These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 17591549

  • 21. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, Boerman OC.
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
    Béhé M, Becker W, Gotthardt M, Angerstein C, Behr TM.
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM.
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [Abstract] [Full Text] [Related]

  • 29. Development of [(90)Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases.
    Ogawa K, Kawashima H, Shiba K, Washiyama K, Yoshimoto M, Kiyono Y, Ueda M, Mori H, Saji H.
    Nucl Med Biol; 2009 Feb; 36(2):129-35. PubMed ID: 19217524
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc.
    Liu CB, Liu GZ, Liu N, Zhang YM, He J, Rusckowski M, Hnatowich DJ.
    Nucl Med Biol; 2003 Feb; 30(2):207-14. PubMed ID: 12623121
    [Abstract] [Full Text] [Related]

  • 34. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
    Yao Z, Zhang M, Axworthy DB, Wong KJ, Garmestani K, Park L, Park CW, Mallett RW, Theodore LJ, Yau EK, Waldmann TA, Brechbiel MW, Paik CH, Pastan I, Carrasquillo JA.
    Cancer Res; 2002 Oct 15; 62(20):5755-60. PubMed ID: 12384535
    [Abstract] [Full Text] [Related]

  • 35. Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
    Hens M, Vaidyanathan G, Welsh P, Zalutsky MR.
    Nucl Med Biol; 2009 Feb 15; 36(2):117-28. PubMed ID: 19217523
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.
    Smith-Jones PM, Pandit-Taskar N, Cao W, O'Donoghue J, Philips MD, Carrasquillo J, Konner JA, Old LJ, Larson SM.
    Nucl Med Biol; 2008 Apr 15; 35(3):343-51. PubMed ID: 18355690
    [Abstract] [Full Text] [Related]

  • 38. Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model.
    Miao Y, Hoffman TJ, Quinn TP.
    Nucl Med Biol; 2005 Jul 15; 32(5):485-93. PubMed ID: 15982579
    [Abstract] [Full Text] [Related]

  • 39. Clinical Dose Preparation of [177Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [177Lu]LuCl3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression.
    Menon SR, Mitra A, Chakraborty A, Tawate M, Sahu S, Rakshit S, Gaikwad S, Dhotre G, Damle A, Banerjee S.
    Cancer Biother Radiopharm; 2022 Jun 15; 37(5):384-402. PubMed ID: 35575711
    [Abstract] [Full Text] [Related]

  • 40. In vivo and in vitro evaluation of 177Lu-labeled DOTA-2-deoxy-D-glucose in mice. A novel radiopharmaceutical agent for cells imaging and therapy.
    Zhang J, Wang Z, Liu H, Cai L, Feng Y, Zhou L, Wei H, Xie Y, Chen Y.
    Hell J Nucl Med; 2019 Jun 15; 22(2):103-110. PubMed ID: 31273351
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.